Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950897 · ClinicalTrials.gov registry record
Muscle Tissue Bank for Muscular Dystrophy
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 21
- Enrollment target
NCT01950897: Completed study, sponsored by Wake Forest University Health Sciences.
NCT01950897 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01950897 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
This protocol proposes to establish gene expression profiles of muscular dystrophies for correct diagnosis and for development of experimental therapies for these diseases.
Primary Outcome
Samples of MD subjects will be compared to samples of non-muscular dystrophy subjects (i.e. control samples).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2005-08-24 |
| Est. Completion | 2015-06-09 |
What the finished NCT01950897 record still lists
NCT01950897 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01950897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01950897 about?
NCT01950897 is a clinical study titled "Muscle Tissue Bank for Muscular Dystrophy". This protocol proposes to establish gene expression profiles of muscular dystrophies for correct diagnosis and for development of experimental therapies for these diseases.
What is the current status of trial NCT01950897?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2005-08-24. Estimated completion is 2015-06-09.
Who is sponsoring clinical trial NCT01950897?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI